Research
Hormonal
Subcellular trafficking of signaling molecules, such as the localization of mTOR to the lysosomal membrane, is a key regulatory event in the control of muscle protein synthesis, in addition to phosphorylation.
Research is uncovering more complex mechanisms behind muscle growth, such as how signaling molecules move within cells. While this doesn't change immediate training advice, it highlights the complexity of muscle adaptation.
ModerateSupportsMEDIUM confidence
There is now growing evidence to suggest that in addition to phosphorylation, the subcellular trafficking of signaling molecules may be an important regulatory event in the cell growth [49&].
Why this rating
Based on cell and animal studies; human data is noted as lacking.
Source
Assessing the regulation of skeletal muscle plasticity in response to protein ingestion and resistance exercise
Chris McGlory et al. · Current Opinion in Clinical Nutrition & Metabolic Care · 2014
DOI 10.1097/mco.0000000000000083
narrative_reviewCited 15×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Frequent episodic bouts of resistance exercise combined with protein ingestion result in skeletal muscle hypertrophy, primarily by driving increases in muscle protein synthesis (MPS) rather than changes in muscle protein breakdown (MPB).Good
- The D2O stable isotopic tracer methodology allows for the assessment of muscle protein synthesis (MPS) over extended periods (days to weeks) in free-living settings, overcoming the limitations of short-term infusion methods.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →